Compositions and methods for the treatment of hemoglobinopathies
AssigneesNovartis AG, Intellia Therapeutics, Inc.
InventorsAnthony Edward BOITANO, Michael COOKE, Lloyd B. KLICKSTEIN, Reynald LESCARBEAU, Craig Stephen MICKANIN, Kabungo MULUMBA, Seshidhar Reddy POLICE, Jennifer SNEAD, Susan C. STEVENSON, Morag STEWART, Yi YANG
Life of this patent
Estimating the term…
Abstract
The present invention is directed to genome editing systems, reagents and methods for the treatment of hemoglobinopathies.
Claims23
-230. (canceled)
A gRNA molecule comprising a tracr and crRNA, wherein the crRNA comprises a targeting domain that is complementary with a target sequence of a human BCL11a gene, a human BCL11a enhancer, or a human HPFH region, wherein
- (a) the target sequence is of the human BCL11a gene, and the targeting domain comprises any one of SEQ ID NO:
- 1 to SEQ ID NO:
- 85 or SEQ ID NO:
- 400 to SEQ ID NO:
- 1231, or a fragment thereof;
- (b) the target sequence is of the human BCL11a enhancer, and the targeting domain comprises any one of SEQ ID NO:
- 182 to SEQ ID NO:
- 277, or SEQ ID NO:
- 278 to SEQ ID NO:
- 333, or SEQ ID NO:
- 334 to SEQ ID NO:
- 341, or SEQ ID NO:
- 1232 to SEQ ID NO:
- 1499, or SEQ ID NO:
- 1596 to SEQ ID NO:
- 1691, or a fragment thereof;
- or
- (c) the target sequence is of the human HFPH region, and the targeting domain comprises any one of SEQ ID NO:
- 86 to SEQ ID NO:
- 181, SEQ ID NO:
- 1500 to SEQ ID NO:
- 1595, or SEQ ID NO:
- 1692 to SEQ ID NO:
- 1761, or a fragment thereof.
A cell comprising an indel shown in FIG. 25, Table 15, Table 26, Table 27, or Table 37.
Dependencies are inferred from the claim text.